Thursday , 18 July 2019
Breaking News

Tag Archives: reddy

Dr. Reddy’s Lab launches Phytonadione Injectable Emulsion in US

Mumbai : Dr. Reddy’s Laboratories has launched Phytonadione Injectable Emulsion USP, 10 mg/ml Single-Dose Ampules, a therapeutic equivalent generic version of Vitamin K1 (Phytonadione) Injectable Emulsion USP, 10 mg/ml, approved by the US Food and Drug Administration (USFDA). The Vitamin K1 (Phytonadione) for Injectable Emulsion USP, 10 mg/ml brand and generic had combined US sales of approximately $46.6 million MAT ... Read More »

Dr. Reddy’s Lab enters into definitive agreement with Upsher-Smith Laboratories, LLC

Dr. Reddy’s Laboratories has entered into a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC (Upsher-Smith), pursuant to which the company would sell its US and select territory rights for Zembrace Symtouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg, (formerly referred to as ‘DFN-02’), which are commercialized through its wholly owned subsidiary, Promius Pharma, LLC. Under ... Read More »

Dr. Reddy’s Lab re-launches Zenatane

Dr. Reddy’s Laboratories has re-launched Zenatane (Isotretinoin Capsules, USP), 10 mg, 20 mg, 30 mg and 40 mg a therapeutic equivalent generic version of Accutane, approved by the US Food and Drug Administration (USFDA). The product is being launched with an approved Risk Evaluation and Mitigation Strategy (REMS) Program. Zenatane (Isotretinoin Capsules, USP), 10 mg, 20 mg, 30 mg and ... Read More »

Jagan Reddy to take oath as Andhra Chief Minister on 30th May

In Andhra Pradesh, YSR Congress Chief YS Jagan Mohan Reddy will take oath as new Chief Minister of the state on May 30 in Vijayawada. Along with the party leaders, Jagan Reddy met Governor ESL Narasimhan,  in Hyderabad yesterday and handed over the copy of resolution electing him unanimously the leader of the legislature party. Later, Jagan Mohan Reddy met ... Read More »

Dr Reddy’s Lab to spend upto $300 million on R&D in FY20

Dr Reddy’s Laboratories is planning to spend upto $300 million on research and development (R&D) during financial year 2019-2020 (FY20). The R&D spends for the January-March quarter of FY19 is $53 million. The company will continue to focus on R&D for some interesting pipeline of proprietary products. But, on an overall basis, the R&D spend would be lower in proprietary ... Read More »

Dr. Reddy’s Lab surges on launching Daptomycin for Injection

Dr. Reddy’s Laboratories is currently trading at Rs. 2851.85 up by 45.70 points or 1.63% from its previous closing of Rs. 2806.15 on the BSE. The scrip opened at Rs. 2804.10 and has touched a high and low of Rs. 2845.00 and Rs. 2800.00 respectively. So far 2912 shares were traded on the counter. The BSE group ‘A’ stock of face ... Read More »

Dr. Reddy’s Lab launches Testosterone Gel

Dr. Reddy’s Laboratories has launched Testosterone Gel 1.62%, a therapeutic equivalent generic version of AndroGel (testosterone gel) 1.62%, approved by the US Food and Drug Administration (USFDA). The AndroGel (testosterone gel) brand and generic had US sales of approximately $815.6 million MAT for the most recent twelve months ending in February 2019 according to IQVIA Health. Dr. Raddy’s Testosterone Gel ... Read More »

Jana Sena Party candidate S P Y Reddy dies after prolonged illness

Sitting MP from Nandyal constituency in Andhra Pradesh S P Y Reddy died after prolonged illness at a hospital in Hyderabad on Tuesday.  He was 68. Reddy was hospitalised early this month. He was elected to the Lok Sabha from Nandyal in 2004 and 2009 as Congress candidate. In 2014, he won the seat as YSR Congress nominee, but jumped ... Read More »

Dr. Reddy’s Lab to acquire portfolio of 42 ANDAs in US

Dr. Reddy’s Laboratories has entered into a definitive agreement to acquire a portfolio of 42 approved, non-marketed Abbreviated New Drug Applications (ANDAs) in the US. The portfolio includes more than 30 generic injectable products. These products will require to be technology transferred and could be launched within the next one to two years. The value of total addressable market for ... Read More »

Dr. Reddy’s Laboratories launches B2B customer service portal ‘XCEED’

Dr. Reddy’s Laboratories has launched B2B customer service portal ‘XCEED’ to increase the operational efficiency. The portal is focused on meeting the growing demand for the company’s portfolio of generic active pharmaceutical ingredients (APIs). The platform will be presented for the first time to customers during DCAT week in New York from March 18 to 21, 2019 and will be ... Read More »

Dr. Reddy’s launches Sevelamer Carbonate for Oral Suspension in US Market

Dr. Reddy’s Laboratories has launched Sevelamer Carbonate for Oral Suspension, in 0.8 g and 2.4 g packets, a therapeutic equivalent generic version of Renvela (sevelamer carbonate) for Oral Suspension, approved by the U.S. Food and Drug Administration (USFDA). The Renvela brand and generic had U.S. sales of approximately $101 million MAT for the most recent twelve months ending in October ... Read More »